Healthcare Industry News: drug-eluting stent
News Release - May 6, 2008
MIV Therapeutics Featured in Cardiovascular Business News
Article Details Potential for Company's VESTAsync(TM) drug-eluting stent (DES)ATLANTA, GA--(Healthcare Sales & Marketing Network)--May 6, 2008 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB ) (Frankfurt:MIV.F ) (http://www.mivtherapeutics.com), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, was featured in Cardiovascular Business News, a newsweekly concerning cardiovascular medicine.
The article, titled "MIV Therapeutics CEO Discusses Role of Second-Generation DES," provides an overview of MIV's VESTAsync DES, detailing "the potential for the company's second-generation VESTAsync drug-eluting stent (DES), the impressive nine-month preliminary results of its first human trial and the emerging position for second-generation stents in the field of interventional cardiology with regards to stricter FDA guidance."
VESTAsync is coated with a polymer-free nanoscale microporous hydroxyapatite. MIV has created a drug-delivery system utilizing the thinnest struts with the lowest profile and highest flexibility in comparison to products currently available on the market. The company recently announced that it achieved preliminary nine-month human data affirming the excellent safety and efficacy of VESTAsync.
"With this system, we actually came up with a drug-delivery coating 0.6 of micron thick versus the other DES that are anywhere from five microns to fifteen microns thick," the article quotes Dr. Mark Landy, Chief Executive Officer of MIV Therapeutics. "The coating is extremely flexible along with the benefits of being thin, which makes our DES more user-friendly and deliverable than those on the market. MIV's stent is also a totally polymer-free system, made from products that occur naturally, which is a more biocompatible system."
The Cardiovascular Business News piece goes on to highlight other remarkable aspects of the VESTAsync and MIV's preliminary data, with Dr. Landy weighing in on aspects of the FDA regulatory approval process. MIV plans to initiate a larger international trial at an as-yet-to-be released the location.
To view a copy of the article, please visit the following link: http://www.cardiovascularbusiness.com/index.php?option=com_content&task=view&Itemid=1&id=1159
About MIV Therapeutics
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents, as well as for a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. This coating platform is derived from hydroxyapatite (HAp), an organic material that has demonstrated excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth, and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on HAp could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIV Therapeutics has a Collaborative Research Agreement with the University of British Columbia and has received a government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program. Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization. MIV's intellectual property portfolio includes patents held by the University of British Columbia and exclusively licensed to MIV. Key patent applications filed simultaneously in various countries around the world further protect the commercial exclusivity of MIV's inventions in the global marketplace. For more information, please visit www.mivtherapeutics.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. All statements that discuss expectations and projections with respect to future matters including, without limitation, statements relating to the safety and efficacy of the Company's product and the ability of the Company's product to rejuvenate the stent market are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, market acceptance of the Company's product, the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated, and other factors identified in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's annual report on Form 10-K for the year ended May 31, 2007 and Forms 10-Q. The Company expressly disclaims any obligation to update publicly or otherwise revise these statements, whether as a result of new information, future events or otherwise, except to the extent required by law.
Source: MIV Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
